A transformative drug discovery platform for allosteric kinase inhibitors
Active Project Grant Awarded Last action
- Award ID
- R01CA255513
- Recipient
-
Regents Of The University Of Minnesota UEI KABJZBBJ4B54
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,036,656
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 94% complete
- Originally
- Funding
-
- $7,440,342.00 Federal
- $596,314.00 Non-federal
- Place of performance
- Minneapolis, MN 55455, USA
Award details come from USAspending.gov.
Description
- Abstract
- The university of minnesota (UMN) and photonic pharma (PP) a minnesota-based drug discovery start-up, have partnered to optimize, field-test, and deploy at industrial scale, an innovative new approach to developing allosteric kinase inhibitors (AKI). These molecules have high potential as novel cancer therapeutics that circumvent clinical resistance to conventional orthosteric kinase inhibitors (OKI). We have developed high- throughput screening (HTS) technology based on nanosecond fluorescence lifetime (FLT) detection of förster resonance energy transfer (fret), that tracks ligand-driven kinase allostery with angstrom precision by monitoring structural changes of the activation loop, the key regulatory element in all kinases. This is the first HTS-amenable technology that accurately resolves allosteric effects of kinase inhibitors, relying on high-quality nanosecond FLT readouts unavailable from conventional fluorescence plate readers (PR). PP have developed a proprietary HTS platform that uses fret biosensors and a state-of-the-art FLT-PR to detect structural readouts in
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $70,609 | $0 | |
| Amendment | $70,609 | $0 | |
| Amendment | $635,484 | $0 | |
| Amendment | $635,484 | $0 | |
| Amendment | $635,484 | $0 | |
| Amendment | $431,555 | $0 | |
| Amendment | $431,555 | $0 | |
| Amendment | $431,555 | $0 | |
| Amendment | $571,741 | $0 | |
| Amendment | $571,741 | $0 | |
| Amendment | $571,741 | $0 | |
| Amendment | $46,674 | $0 | |
| Amendment | $46,674 | $0 | |
| Amendment | $46,674 | $0 | |
| Amendment | $525,067 | $0 | |
| Amendment | $525,067 | $0 | |
| Amendment | $596,314 | $0 | |
| Original award | $596,314 | $596,314 |
Show all 19
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Photonic Pharma LLC | $1,101,861 |
Quick answers
Who received award R01CA255513?
R01CA255513 was awarded to Regents Of The University Of Minnesota by National Cancer Institute (National Institutes of Health) on March 1, 2021.
How much is award R01CA255513 worth?
$8,036,656 has been obligated on R01CA255513: $7,440,342 in federal funding and $596,314 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award